Skip to content

Role of MR Spectroscopy in Brain Tumors

Role of Magnetic Resonance Spectroscopy in Differentiating Brain Tumors

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03619694
Enrollment
100
Registered
2018-08-08
Start date
2017-09-01
Completion date
2018-10-01
Last updated
2018-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Neoplasms

Brief summary

In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion

Detailed description

Proton magnetic resonance spectroscopy (H-MRS) may be helpful in suggesting tumor histology and tumor grade and may better define tumor extension and the ideal site for biopsy compared with conventional magnetic resonance (MR) imaging. A multifunctional approach with diffusion-weighted imaging, perfusion-weighted imaging, and permeability maps, along with H-MRS, may enhance the accuracy of the diagnosis and characterization of brain tumors and estimation of therapeutic response. Integration of advanced imaging techniques with conventional MR imaging and the clinical history help to improve the accuracy, sensitivity, and specificity in differentiating tumors and nonneoplastic lesions.

Interventions

DEVICEMRI Spectroscopy

Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* All patients with space-occupying lesions

Exclusion criteria

* Post operative cases * Non-neoplastic nature

Design outcomes

Primary

MeasureTime frameDescription
Comparison of MRS findings with the pathology of the specimensBaselineAnalysis of the MRS metabolites peaks and integral and test if they can differentiate the grades of brain tumors

Countries

Egypt

Contacts

Primary ContactMohamed AbdelWahab, Msc
dr.assiut@gmail.com01148918822

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026